Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$2.25 - $3.07 $56,607 - $77,238
-25,159 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$2.6 - $4.21 $12,266 - $19,862
-4,718 Reduced 15.79%
25,159 $72,000
Q1 2019

May 15, 2019

BUY
$3.05 - $4.34 $37,426 - $53,256
12,271 Added 69.7%
29,877 $125,000
Q4 2018

Feb 14, 2019

BUY
$2.82 - $4.67 $49,648 - $82,220
17,606 New
17,606 $55,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $472M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Weiss Asset Management LP Portfolio

Follow Weiss Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Asset Management LP with notifications on news.